This page shows you the latest news items in this category. This is page number 8.
Total 2840 results found since Jan 2013.
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Manny Machado continues to drive Padres ' success
SAN DIEGO -- In a suite at the Delano hotel in Las Vegas during the 2018 Winter Meetings, the Padres front office was growing frustrated. They didn't like the price tags on some of free agency's... #sandiego #freeagency #lasvegas #padres #mannymachado #delano #wintermeetings
Source: Reuters: Health - October 14, 2022 Category: Consumer Health News Source Type: news
Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
IRVINE, Calif. – Sept. 27, 2022 – Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight , TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light ...
Source: Johnson and Johnson - September 28, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Joins Forces with Pro Football Hall-of-Famer Shannon Sharpe to Address Health Disparities in Prostate Cancer
HORSHAM, P.A., September 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of Talk That TalkTM, an educational campaign and call to action to drive prostate cancer awareness and reinforce the importance of screening for early detection among Black men. Utilizing a new educational website and social media channels, Talk That TalkTM creates safe and supportive spaces to learn about prostate cancer, share resources, and take proactive steps to live healthier lives. The ultimate goal is to encourage and elevate the importance of consistent prostate cancer screenings to help r...
Source: Johnson and Johnson - September 18, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Building the right support for people with a learning disability and autistic people, DHSC (updated 19th August 2022)
An action plan to strengthen community support for people with a learning disability and autistic people, and reduce reliance on mental health inpatient care.
19 August 2022Added HTML versions of Building the Right Support Action Plan and the Table of Commitments.
14 July 2022First published.
Source: Current Awareness Service for Health (CASH) - August 22, 2022 Category: Consumer Health News Source Type: news
How to be a rockstar blogger – part 5
Write consistently – themes, timing, timeless
The best tip I can give you about becoming a Rock Star Blogger is to write consistently both in time and subject. Writing on your blog on a daily basis is a must for those starting out if you want to have a chance of competing with others in your field. If you can’t do it daily, then you need to be thinking in terms of several times each week. Once a week is a poor third and it will take you much longer to reach any goals you have set yourself.
When I ran the Hysterectomy Association I would write on a daily basis for the first five years, remember this was the early ...
Source: The Hysterectomy Association - August 17, 2022 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Writing Business blogging rockstar blogger Source Type: news
Viewers Unmoved By Price Info in Heart Drug Commercials
(MedPage Today) -- Disclosure of moderate price tags in direct-to-consumer advertising (DTCA) did not put the brakes on people wanting to switch medications after viewing commercials for heart drugs, online studies showed.
Among survey participants...
Source: MedPage Today Public Health - August 12, 2022 Category: American Health Source Type: news
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of ageThe FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years o...
Source: Roche Investor Update - August 12, 2022 Category: Pharmaceuticals Source Type: news
FDA Warns Amazon, Other Vendors About Sale of Skin Tag Removal Products
WEDNESDAY, Aug. 10, 2022 -- The U.S. Food and Drug Administration on Tuesday issued warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags.
No over-the-counter medications have FDA...
Source: Drugs.com - Pharma News - August 10, 2022 Category: Pharmaceuticals Source Type: news
B 8/10 -- FDA Warns Amazon, Other Vendors About Sale of Skin Tag Removal Products
WEDNESDAY, Aug. 10, 2022 – The U.S. Food and Drug Administration on Tuesday issued warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags.
No over-the-counter medications have FDA...
Source: Drugs.com - Daily MedNews - August 9, 2022 Category: General Medicine Source Type: news
FDA Warns Amazon, Other Vendors About Sale of Skin Tag Removal Products
WEDNESDAY, Aug. 10, 2022– The U.S. Food and Drug Administration on Tuesday issued warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags.
No over-the-counter medications have...
Source: Drugs.com - Daily MedNews - August 9, 2022 Category: General Medicine Source Type: news
Dr. Raymond Damadian, father of MRI, dies at 86
Dr. Raymond Damadian, considered by many to be the "father of MRI," died o...Read more on AuntMinnie.comRelated Reading:
Damadian credits divine influence for MRI's earliest milestone
Conflict over recognition for MRI discovery resurfaces at ECR
Did Damadian’s mercurial past cost him the Nobel Prize?
Fonar presses case for Damadian recognition
Fonar NYT ad decries 'shameful wrong' in MRI Nobel awardComments:
8/8/2022 10:31:36 AMfw
That's just not correct. Nothing in today's MRI usess the principles he proposed.
8/8/2022 10:55:04 AMNYPhD
"On June 30 the United States Court of Appeals for the Federal ...
Source: AuntMinnie.com Headlines - August 8, 2022 Category: Radiology Source Type: news
European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
